Teva reports Phase III data for thrice-weekly Copaxone

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said thrice-weekly 40 mg subcutaneous Copaxone glatiramer met the primary endpoint of reducing annualized relapse rate (ARR) at 12 months vs. placebo in the Phase III GALA trial to treat relapsing-remitting multiple sclerosis (RRMS). Specifically, Copaxone reduced ARR at 12 months by 34.4% vs. placebo (p<0.001). The most common adverse events were injection-site reactions, headaches and nasopharyngitis. The double-blind, international trial enrolled than 1,400 patients. ...